|
|
||||||||
1 Central Laboratory, Norwegian Radium Hospital, Montebello, N-0310 Oslo, Norway.
aAuthor for correspondence. Fax 47-22-730725; e-mail johan.bjerner{at}klinmed.uio.no.
Background: The primary aim of the study was to reduce interference in an in-house two-site, two-step immunometric assay.
Methods: In the running laboratory routine, 11 261 samples were tested with a carcinoembryonic antigen (CEA) assay with bovine immunoglobulin but no murine immunoglobulins in the buffer, in parallel to our routine CEA assay, using 15 mg/L heat-treated nonspecific murine immunoglobulin (MAK33) in the buffer and with the Fc fragments removed from the capture antibody.
Results: The frequency of interference was estimated to be 4.0% (95% confidence interval, 3.34.7%). The addition of 15 mg/L native MAK33 had little effect (frequency, 3.9%; 95% confidence interval, 3.24.6%), whereas adding 15 mg/L heat-treated MAK33 reduced interference to 0.86% (0.611.12%), and adding 50 mg/L reduced it further to 0.06% (00.13%). Removing the Fc fragments by itself reduced interference to 0.10% (0.020.19%). There were no statistically significant differences for age (P <0.23) or gender (P <0.40) between patients with interference (n = 210) and a randomly selected interference-negative control group (n = 186). Interference was not constant in patients: 15 of 25 individuals positive for interference and with four or more samples screened for interference had an interference-negative sample either before or after the peak of interference.
Conclusions: In a two-site, two-step immunometric assay using mouse monoclonal antibodies, use of heat-treated nonspecific murine immunoglobulin in the buffer or removal of the Fc fragment from the capture antibody could improve performance.
The following articles in journals at HighWire Press have cited this article:
![]() |
M. S. Nordlund, D. J. Warren, K. Nustad, J. Bjerner, and E. Paus Automated Time-Resolved Immunofluorometric Assay for Progastrin-Releasing Peptide Clin. Chem., May 1, 2008; 54(5): 919 - 922. [Abstract] [Full Text] [PDF] |
||||
![]() |
U.-H. Stenman Improving Immunoassay Performance by Antibody Engineering Clin. Chem., May 1, 2005; 51(5): 801 - 802. [Full Text] [PDF] |
||||
![]() |
D. J. Warren, J. Bjerner, E. Paus, O. P. Bormer, and K. Nustad Use of an In Vivo Biotinylated Single-Chain Antibody as Capture Reagent in an Immunometric Assay to Decrease the Incidence of Interference from Heterophilic Antibodies Clin. Chem., May 1, 2005; 51(5): 830 - 838. [Abstract] [Full Text] [PDF] |
||||
![]() |
J. Bjerner, O. P. Bormer, and K. Nustad The War on Heterophilic Antibody Interference Clin. Chem., January 1, 2005; 51(1): 9 - 11. [Full Text] [PDF] |
||||
![]() |
C. M. Preissner, L. A. Dodge, D. J. O'Kane, R. J. Singh, and S. K.G. Grebe Prevalence of Heterophilic Antibody Interference in Eight Automated Tumor Marker Immunoassays Clin. Chem., January 1, 2005; 51(1): 208 - 210. [Full Text] [PDF] |
||||
![]() |
A. A.A. Ismail A Radical Approach Is Needed to Eliminate Interference from Endogenous Antibodies in Immunoassays Clin. Chem., January 1, 2005; 51(1): 25 - 26. [Full Text] [PDF] |
||||
![]() |
C. M. Preissner, D. J. O'Kane, R. J. Singh, J. C. Morris, and S. K. G. Grebe Phantoms in the Assay Tube: Heterophile Antibody Interferences in Serum Thyroglobulin Assays J. Clin. Endocrinol. Metab., July 1, 2003; 88(7): 3069 - 3074. [Abstract] [Full Text] [PDF] |
||||
![]() |
U.-H. Stenman Standardization as a Private Enterprise Clin. Chem., April 1, 2003; 49(4): 535 - 536. [Full Text] [PDF] |
||||
![]() |
A. A.A. Ismail, P. L. Walker, J. H. Barth, K. C. Lewandowski, R. Jones, and W. A. Burr Wrong Biochemistry Results: Two Case Reports and Observational Study in 5310 Patients on Potentially Misleading Thyroid-stimulating Hormone and Gonadotropin Immunoassay Results Clin. Chem., November 1, 2002; 48(11): 2023 - 2029. [Abstract] [Full Text] [PDF] |
||||
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |